Search

Introdução: O carcinoma epidermoide é uma patologia que corresponde a 90% dos tumores malignos da cavidade oral. Objetivo: Avaliar o perfil epidemiológico, o tratamento e a sobrevida dos pacientes diagnosticados com carcinoma epidermoide oral em um hospital referência na Região Norte do Estado do Rio Grande do Sul, Brasil. Método: Estudo observacional retrospectivo, com análise dos prontuários dos pacientes com diagnóstico dessa patologia, no período de 1993 a 2008, no banco de dados desse hospital. Os dados foram analisados pelo programa estatístico SPSS versão 18 utilizando testes paramétricos e não paramétricos. Resultados: Foram coletados e analisados dados de 303 prontuários que revelaram que 88,4% eram homens, leucodermas, com maior incidência na faixa etária entre 51 e 60 anos. A associação de álcool e tabaco foi observada em 84,7% dos pacientes. O local mais afetado foi a língua (45,5%) e a maioria dos casos apresentou estádios tardios III e IV com uma sobrevida de 17,83 meses. Embora o tratamento cirúrgico tenha sido o mais realizado (55,9%) e apresentado a maior sobrevida, não foi observada significância estatística deste com relação aos demais tratamentos (p=0,185). Conclusão: O perfil epidemiológico dos pacientes é muito semelhante aos registros de vários países. Neste caso, o diagnóstico tardio diminuiu significativamente a expectativa de vida dos pacientes (2,5x), e o tratamento executado bem como o local inicial da lesão não tiveram influência significativa na sobrevida.

OBJECTIVES This study evaluated the effectiveness of hydrogen peroxide (H2O2) as mouthwash and nasal spray on symptom relief in coronavirus disease 2019 (COVID-19) patients. METHODS Patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), who were treated in a hospital or at home, and patients’ family members (not positive for SARS-CoV-2), were randomized into 2 groups: experimental (1% H2O2 for gargling, 0.5% H2O2 for nasal wash), and control. Patients gargled the solution 3 times a day, and applied the nasal spray twice a day, for a 7-day period. Family members received the same treatment as the treated COVID-19 patient. The researchers contacted patients every 2 days over an 8-day period. An average post-treatment interval of 8 days passed before testing family members. RESULTS The most frequent symptoms on day 0 were cough, loss of taste, and hyposmia; there were no significant differences between groups, independent of the period. The symptom of dyspnea presented a significant difference between days 2 and 4 (p

OBJECTIVES To evaluate the effectiveness of hydrogen peroxide (H2O2) in the form of mouthwash and nasal spray as an auxiliary treatment for coronavirus disease 2019 (COVID-19). METHODS Forty hospitalized patients who tested positive for severe acute respiratory syndrome coronavirus 2 using a reverse-transcription polymerase chain reaction test were evaluated. They were randomly divided into an experimental group (n= 20; gargling with 1.0% H2O2 and nasal wash with 0.5% H2O2) or a control group (n= 20). The solutions were used for 7 days and the patients were monitored every 2 days, for a total of 8 days. At check-ups, patients were asked about their symptoms and possible adverse effects of the solutions. The presence and severity (mild, moderate, or severe) of symptoms were recorded. Data were compared using the Student test and the Fisher exact test (α= 0.05). RESULTS There was no significant difference between the 2 groups in the length of hospital stay (p= 0.65). The most frequent symptom on day 0 was coughing (72.0% in the experimental group and 76.5% in the control group), which abated over time. There was no significant difference between the groups in the evaluated symptoms. Most (75.0%) of the patients in the experimental group presented a reduction in dyspnea between days 0 and 2. Few patients reported adverse effects from the use of the solutions. CONCLUSIONS H2O2 as a mouthwash and nasal spray is safe to use. There is insufficient evidence to demonstrate that H2O2 is effective as an auxiliary treatment for hospitalized COVID-19 patients.